FDA advisers endorse Celebrex for juvenile rheumatoid arthritis: lack of studies in children raises safety concerns.
Young
Donna
D
D000293:Adolescent; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D035843:Biomedical Research; D000068579:Celecoxib; D017277:Drug Approval; D004341:Drug Evaluation; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D000894:Anti-Inflammatory Agents, Non-Steroidal; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib